• Adlai Nortye dosed the first U.S. patient in the intermittent weekly arm of its global Phase 1 trial for pan-RAS(ON) inhibitor AN9025.
• Both once-daily and once-weekly dose-escalation arms are enrolling in advanced or metastatic solid tumors with RAS mutations.
• Management targets initial Phase 1 dose-escalation data from the once-daily arm in 1H27, with a potential early look at weekly dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160700PRIMZONEFULLFEED9763323) on July 16, 2026, and is solely responsible for the information contained therein.